For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Astellas to Bring Global Development, Regulatory Affairs Functions Under Control of Chief Medical Officer
February 7, 2014
- JCR, GSK Ink Research Support Agreement to Establish New Technology
February 6, 2014
- Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
- Fujifilm Pharma Gets Japan Distribution Rights for Sosei’s Oropharyngeal Candidiasis Drug
February 6, 2014
- Kyowa Kirin Begins Japan PIII Trial of ARQ 197 for Hepatocellular Cancer
February 6, 2014
- Eisai to File Lenvatinib for Approval in Japan, US, Europe as Early as June
February 6, 2014
- NDA for Lorcaserin Expected to Be Filed in Japan in FY2016 or Later: Eisai
February 5, 2014
- 396 Eisai Workers Take Voluntary Retirement, FY2013 Net Profit Forecast Revised Downward
February 5, 2014
- DSP Expands Collaboration with Edison for Development of Mitochondrial Disease Treatment
February 5, 2014
- Kyowa Kirin to Integrate Research and Development Divisions
February 4, 2014
- Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
- Kyowa Kirin Drug Prices Expected to Slip by 7% Due to NHI Price Revision
February 4, 2014
- Asahi Kasei Pharma to Discontinue Development of Teribone Transdermal Patch Formulation in Japan
February 4, 2014
- Impact of FDA’s Ranbaxy Ban on Daiichi Sankyo Earnings “Unavoidable”: Mr Sakai
February 3, 2014
- Daiichi Sankyo to Shift to IFRS Starting from FY2013
February 3, 2014
- CSL Behring Launches Hizentra, 1st SC Immunoglobulin Therapy in Japan
February 3, 2014
- Teijin Picks Another Pharma Maven for President
February 3, 2014
- Chugai President Mum on Kadcyla Launch Timing, Price Talks with Regulators Still Ongoing
February 3, 2014
- Chugai Sales Climb 9.6%, Actemra Sales Exceed 100 Billion Yen
February 3, 2014
- Sanofi Demands Payment of $416 Million from Novartis over Dissolved Equa Deal
January 31, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…